查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026733

病毒性腸胃炎市場預測至2034年－全球分析（按類型、診斷、治療、藥物、劑量、適應症、給藥途徑、分銷管道、最終用戶和地區分類）

Viral Gastroenteritis Market Forecasts to 2034 - Global Analysis By Type, Diagnosis, Treatment, Drug, Dosage, Indication, Route of Administration, Distribution Channel, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球病毒性腸胃炎市場規模將達到 570 億美元，並在預測期內以 6.6% 的複合年成長率成長，到 2034 年將達到 951 億美元。

腸胃炎（也稱為病毒性腸胃炎）是一種感染性腸道疾病，會導致腸道和胃部的發炎。輪狀病毒、腺病毒和諾羅病毒是主要的致病病毒。由於其傳染性極強，通常透過受污染的食物或水傳播，或透過與感染者密切接觸傳播。此外，腹瀉、嘔吐、腹部絞痛、發燒和噁心是常見症狀，嚴重時可導致脫水。

根據美國健身和健康公司 Bodibio 進行的一項調查，該調查涉及 33 個國家的 73,076 名成年人，40% 的受訪者表示患有功能性胃腸道疾病，包括所有類型，如功能性消化不良、大腸激躁症和功能性便秘。

病毒傳播

輪狀病毒和諾羅病毒等引起腸胃炎的病毒具有極高的傳染性，這是疫情傳播的主要因素。病毒主要透過人與人之間的接觸、嘔吐物產生的氣溶膠、受污染的表面傳播。此外，這種高傳染性也導致病毒性腸胃炎的迅速和廣泛爆發，尤其是在人口密集的環境和人際接觸密切的社區。

缺乏特異性抗病毒治療方法

缺乏針對包括諾羅病毒在內的許多致病病原體的特異性抗病毒藥物，是治療病毒性腸胃炎的一大障礙。與通常使用抗生素治療的細菌感染疾病不同，病毒性腸胃炎的症狀治療主要著重於補充液體和緩解症狀。此外，缺乏標靶抗病毒藥物也限制了治療性介入的選擇。

疫苗研發

針對腸胃炎病毒（尤其是諾羅病毒）的強效疫苗研發工作具有巨大潛力。深入了解宿主免疫反應和病毒基因組可能有助於開發新的疫苗研發方法。此外，疫苗的成功研發有望徹底改變預防措施，並降低腸胃炎集體爆發的發生率和嚴重性。

缺乏特異性抗病毒療法

一大挑戰是缺乏針對多種腸胃炎病毒的特異性抗病毒藥物。病毒性腸胃炎的治療主要依賴支持療法，與細菌感染疾病（可經常使用標靶抗生素）不同，其治療性介入選擇有限。此外，缺乏標靶抗病毒治療方法也使得重症病例的治療更加困難。

新冠疫情的影響：

病毒性腸胃炎市場受到新冠肺炎疫情的影響。由於全球醫療系統將主要精力集中在控制疫情上，病毒性腸胃炎的病例數出現波動。為遏制新冠肺炎傳播而實施的封鎖、社交距離和改善衛生習慣等措施，在一定程度上減少了腸胃炎病毒的傳播。此外，民眾的注意力和資源轉移到疫情上，監測力度減弱，以及醫療服務中斷，都使得準確追蹤和管理腸胃炎病例變得困難。

在預測期內，輪狀病毒部分預計將是最大的部分。

由於其對全球公共衛生的廣泛影響，輪狀病毒在病毒性腸胃炎領域佔據主導地位，擁有最大的市場佔有率。此外，輪狀病毒感染疾病是導致嚴重腹瀉的主要原因之一，尤其是在幼兒身上。它還會顯著增加與腸胃炎相關的總體發病率和死亡率。由於該病毒具有高度傳染性且能適應各種環境，因此經常出現在各種場所，包括托兒機構和醫療資源匱乏的地區。

在預測期內，門診診所細分市場預計將呈現最高的複合年成長率。

門診中心板塊以最高的複合年成長率成長，在醫療保健領域的重要性日益凸顯。這些中心對於醫療服務模式的轉型至關重要，因為它們專注於提供門診護理、診斷和預防醫學服務。此外，門診護理的成長也得益於以患者為中心的醫療模式的轉變以及對價格合理、便捷的醫療保健服務日益成長的需求。

市佔率最大的地區：

北美地區繼續保持最大的市場佔有率。該地區的領先地位歸功於多種因素的共同作用，包括先進的醫療基礎設施、大量的研發投入、健全的法規結構以及高昂的醫療費用支出。然而，美國憑藉其先進的醫療技術、強大的製藥產業和完善的醫療保健體系，尤其成為北美醫療保健市場的主要驅動力。

複合年成長率最高的地區：

在預測期內，歐洲地區預計將呈現最高的複合年成長率。憑藉其完善的醫療基礎設施、高標準的醫學研究和創新以及廣泛的醫療保健體系，歐洲一直保持著全球醫療保健市場的大部分佔有率。此外，人口老化、慢性病盛行率上升以及對可近性和高品質醫療保健的重視等因素，都促進了歐洲在全球醫療保健領域的持續成長和影響力。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球病毒性腸胃炎市場：依類型分類

  • 諾羅病毒
  • 輪狀病毒
  • 星狀病毒
  • 腸腺病毒
  • 其他類型

第6章 全球病毒性腸胃炎市場：依診斷方式分類

  • 身體檢查
  • 快速糞便檢驗

第7章 全球病毒性腸胃炎市場：依治療方式分類

  • 點滴
  • 運動抑制劑
  • 電解質
  • 止吐藥
  • 止瀉藥
  • 其他治療方法

第8章 全球病毒性腸胃炎市場：依藥物分類

  • 抗生素
  • 制酸劑
  • 瀉藥
  • 化療藥物
  • 其他藥物

第9章 全球病毒性腸胃炎市場：依劑量分類

  • 藥片
  • 注射藥物
  • 其他劑量

第10章 全球病毒性腸胃炎市場：依適應症分類

  • 水樣腹瀉
  • 嘔吐
  • 腹痛和抽搐
  • 頭暈
  • 腹瀉
  • 噁心
  • 嘔吐
  • 頭痛
  • 寒意
  • 食慾不振
  • 發燒
  • 關節僵硬
  • 流汗
  • 肌肉酸痛
  • 減重
  • 其他改編

第11章 全球病毒性腸胃炎市場：依給藥途徑分類

  • 口服
  • 靜脈
  • 其他

第12章 全球病毒性腸胃炎市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第13章 全球病毒性腸胃炎市場：依最終用戶分類

  • 診斷中心
  • 門診部
  • 其他最終用戶

第14章 全球病毒性腸胃炎市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第15章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第16章：公司簡介

  • Bausch Health Companies Inc.
  • Abbott
  • Cipla Inc.
  • Sanofi
  • Bayer AG
  • Allergan
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Private Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals
  • Astellas Pharma Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Eli Lilly and Company
  • Novartis AG
  • Janssen Biotech Inc.
  • Mylan NV
Product Code: SMRC24565

According to Stratistics MRC, the Global Viral Gastroenteritis Market is accounted for $57.0 billion in 2026 and is expected to reach $95.1 billion by 2034 growing at a CAGR of 6.6% during the forecast period. The stomach flu, also referred to as viral gastroenteritis, is an infectious intestinal disease that causes inflammation in the intestines and stomach. The rotavirus, adenovirus, and norovirus are the main viruses that cause it. Being highly contagious, the illness usually spreads through contaminated food, water, or intimate contact with an infected person. Moreover, diarrhea, vomiting, cramps in the abdomen, fever, and nausea are common symptoms; in severe cases, dehydration results.

According to a survey report across 33 countries among 73,076 adults by Bodibio, a US-based fitness and wellness company, 40% of those surveyed had a functional gastrointestinal disorder, including all the variations of functional dyspepsia, irritable bowel syndrome, functional constipation, and others.

Market Dynamics:

Driver:

Spread of viral adherence

The highly contagious nature of viruses that cause gastroenteritis, like rotavirus and norovirus, is a major factor in the spread of outbreaks. Viral transmission occurs mainly through person-to-person contact, aerosolized vomit particles, and contaminated surfaces. Additionally, this increased transmissibility, particularly in crowded environments and communities with close interpersonal contact, plays a role in the quick and widespread occurrence of viral gastroenteritis.

Restraint:

Lack of targeted antiviral treatment

The lack of specific antiviral drugs for many of the causative agents, including norovirus, is a significant barrier to treating viral gastroenteritis. In contrast to bacterial infections, which are typically treated with antibiotics, supportive care for viral gastroenteritis primarily focuses on rehydration and symptom relief. Furthermore, therapeutic intervention options are limited due to the absence of targeted antiviral drugs.

Opportunity:

Development and research on vaccines

Research and development efforts aimed at producing potent vaccines against gastroenteritis viruses, particularly noroviruses, present a substantial opportunity. Novel approaches to the development of vaccines could be made possible by growing comprehension of host immune responses and viral genomics. Moreover, a successful vaccine could transform prophylactic measures and lessen the incidence and intensity of gastroenteritis outbreaks.

Threat:

Absence of particularized antiviral therapy

One major threat is the lack of specific antiviral drugs for many gastroenteritis viruses. Viral gastroenteritis is primarily treated with supportive care, with limited options for therapeutic interventions, unlike bacterial infections, which are frequently treated with targeted antibiotics. Additionally, the management of severe cases is made more difficult by the absence of a targeted antiviral treatment.

Covid-19 Impact:

The market for viral gastroenteritis has been affected by the COVID-19 pandemic. As global healthcare systems have primarily concentrated on controlling the pandemic, there have been variations in the prevalence of viral gastroenteritis cases. In an attempt to stop the spread of COVID-19, lockdowns, social distancing measures, and improved hygiene practices have all somewhat reduced the number of gastroenteritis viruses that are being transmitted. Moreover, accurately tracking and managing gastroenteritis cases has proven difficult, due to changes in public attention and resources towards the pandemic, decreased surveillance efforts, and disruptions in healthcare services.

The Rotavirus segment is expected to be the largest during the forecast period

Due to the widespread influence on public health worldwide, the rotavirus segment is a dominant force in the viral gastroenteritis landscape, possessing the largest market share. Additionally, rotavirus infections are well known for being a major cause of severe diarrhea, particularly in young children. They also significantly increase the overall burden of morbidity and mortality associated with gastroenteritis. Due to the virus's high contagiousness and adaptability to different environments, it is frequently found in a wide range of settings, including childcare facilities and areas with poor access to healthcare.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

With the highest CAGR, the ambulatory care center segment is becoming more and more important in the healthcare sector. These centers are essential to the transformation of healthcare delivery because they are dedicated to providing outpatient services, diagnostics, and preventive care. Furthermore, the growth of ambulatory care has been driven by a shift towards patient-centric models and an increasing demand for affordable and easily accessible healthcare options.

Region with largest share:

North America has continuously held the largest market share. The region's prominence is ascribed to a confluence of factors such as sophisticated healthcare infrastructure, significant investments in research and development, a resilient regulatory framework, and elevated healthcare spending. However, with its sophisticated medical technology, firmly established pharmaceutical industry, and extensive healthcare system, the United States in particular stands out as a major driver of the North American healthcare market.

Region with highest CAGR:

During the forecast period, the European region is expected to have the highest CAGR. Europe consistently holds a sizable share of the global healthcare market thanks to its well-established healthcare infrastructure, high standards for medical research and innovation, and extensive healthcare systems. Moreover, the aging population, the frequency of chronic illnesses, and the emphasis on accessible and high-quality healthcare all support Europe's continued rise and clout in the world healthcare arena.

Key players in the market

Some of the key players in Viral Gastroenteritis market include Bausch Health Companies Inc., Abbott, Cipla Inc., Sanofi, Bayer AG, Allerga, Dr. Reddy's Laboratories Ltd, Johnson & Johnson Private Ltd., Takeda Pharmaceutical Company Ltd., Valeant Pharmaceuticals, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Eli Lilly and Company, Novartis AG, Janssen Biotech Inc. and Mylan N.V.

Key Developments:

In September 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced it has completed its acquisition of XIIDRA(R) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In April 2023, Cipla has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used in the treatment of type 2 diabetes from January 1, 2026.

Types Covered:

  • Norovirus
  • Rotavirus
  • Astrovirus
  • Enteric Adenovirus
  • Other Types

Diagnosis's Covered:

  • Physical Examination
  • Rapid Stool Test

Treatments Covered:

  • Intravenous Fluids
  • Antimotility Agents
  • Electrolytes
  • Antiemetic Drugs
  • Antidiarrheal Drugs
  • Other Treatments

Drugs Covered:

  • Antibiotics
  • Antacids
  • Laxatives
  • Chemotherapy Drugs
  • Other Drugs

Dosages Covered:

  • Tablet
  • Injection
  • Other Dosages

Indications Covered:

  • Watery Diarrhea
  • Vomiting
  • Abdominal Pain and Cramps
  • Dizziness
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Chills
  • Loss of Appetite
  • Fever
  • Joint Stiffness
  • Sweating
  • Muscle Pain
  • Weight Loss
  • Other Indications

Route of Administrations Covered:

  • Oral
  • Intravenous
  • Others

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End Users Covered:

  • Diagnostic Centers
  • Ambulatory Care Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Gastroenteritis Market, By Type

  • 5.1 Introduction
  • 5.2 Norovirus
  • 5.3 Rotavirus
  • 5.4 Astrovirus
  • 5.5 Enteric Adenovirus
  • 5.6 Other Types

6 Global Viral Gastroenteritis Market, By Diagnosis

  • 6.1 Introduction
  • 6.2 Physical Examination
  • 6.3 Rapid Stool Test

7 Global Viral Gastroenteritis Market, By Treatment

  • 7.1 Introduction
  • 7.2 Intravenous Fluids
  • 7.3 Antimotility Agents
  • 7.4 Electrolytes
  • 7.5 Antiemetic Drugs
  • 7.6 Antidiarrheal Drugs
  • 7.7 Other Treatments

8 Global Viral Gastroenteritis Market, By Drug

  • 8.1 Introduction
  • 8.2 Antibiotics
  • 8.3 Antacids
  • 8.4 Laxatives
  • 8.5 Chemotherapy Drugs
  • 8.6 Other Drugs

9 Global Viral Gastroenteritis Market, By Dosage

  • 9.1 Introduction
  • 9.2 Tablet
  • 9.3 Injection
  • 9.4 Other Dosages

10 Global Viral Gastroenteritis Market, By Indication

  • 10.1 Introduction
  • 10.2 Watery Diarrhea
  • 10.3 Vomiting
  • 10.4 Abdominal Pain and Cramps
  • 10.5 Dizziness
  • 10.6 Diarrhea
  • 10.7 Nausea
  • 10.8 Vomiting
  • 10.9 Headache
  • 10.10 Chills
  • 10.11 Loss of Appetite
  • 10.12 Fever
  • 10.13 Joint Stiffness
  • 10.14 Sweating
  • 10.15 Muscle Pain
  • 10.16 Weight Loss
  • 10.17 Other Indications

11 Global Viral Gastroenteritis Market, By Route of Administration

  • 11.1 Introduction
  • 11.2 Oral
  • 11.3 Intravenous
  • 11.4 Others

12 Global Viral Gastroenteritis Market, By Distribution Channel

  • 12.1 Introduction
  • 12.2 Hospital Pharmacy
  • 12.3 Retail Pharmacy
  • 12.4 Online Pharmacy

13 Global Viral Gastroenteritis Market, By End User

  • 13.1 Introduction
  • 13.2 Diagnostic Centers
  • 13.3 Ambulatory Care Centers
  • 13.4 Other End Users

14 Global Viral Gastroenteritis Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 Bausch Health Companies Inc.
  • 16.2 Abbott
  • 16.3 Cipla Inc.
  • 16.4 Sanofi
  • 16.5 Bayer AG
  • 16.6 Allergan
  • 16.7 Dr. Reddy's Laboratories Ltd.
  • 16.8 Johnson & Johnson Private Ltd.
  • 16.9 Takeda Pharmaceutical Company Ltd.
  • 16.10 Valeant Pharmaceuticals
  • 16.11 Astellas Pharma Inc.
  • 16.12 Teva Pharmaceutical Industries Ltd.
  • 16.13 Sun Pharmaceutical Industries Ltd.
  • 16.14 Aurobindo Pharma
  • 16.15 Eli Lilly and Company
  • 16.16 Novartis AG
  • 16.17 Janssen Biotech Inc.
  • 16.18 Mylan N.V.

List of Tables

  • Table 1 Global Viral Gastroenteritis Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Viral Gastroenteritis Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Viral Gastroenteritis Market Outlook, By Norovirus (2023-2034) ($MN)
  • Table 4 Global Viral Gastroenteritis Market Outlook, By Rotavirus (2023-2034) ($MN)
  • Table 5 Global Viral Gastroenteritis Market Outlook, By Astrovirus (2023-2034) ($MN)
  • Table 6 Global Viral Gastroenteritis Market Outlook, By Enteric Adenovirus (2023-2034) ($MN)
  • Table 7 Global Viral Gastroenteritis Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 8 Global Viral Gastroenteritis Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 9 Global Viral Gastroenteritis Market Outlook, By Physical Examination (2023-2034) ($MN)
  • Table 10 Global Viral Gastroenteritis Market Outlook, By Rapid Stool Test (2023-2034) ($MN)
  • Table 11 Global Viral Gastroenteritis Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 12 Global Viral Gastroenteritis Market Outlook, By Intravenous Fluids (2023-2034) ($MN)
  • Table 13 Global Viral Gastroenteritis Market Outlook, By Antimotility Agents (2023-2034) ($MN)
  • Table 14 Global Viral Gastroenteritis Market Outlook, By Electrolytes (2023-2034) ($MN)
  • Table 15 Global Viral Gastroenteritis Market Outlook, By Antiemetic Drugs (2023-2034) ($MN)
  • Table 16 Global Viral Gastroenteritis Market Outlook, By Antidiarrheal Drugs (2023-2034) ($MN)
  • Table 17 Global Viral Gastroenteritis Market Outlook, By Other Treatments (2023-2034) ($MN)
  • Table 18 Global Viral Gastroenteritis Market Outlook, By Drug (2023-2034) ($MN)
  • Table 19 Global Viral Gastroenteritis Market Outlook, By Antibiotics (2023-2034) ($MN)
  • Table 20 Global Viral Gastroenteritis Market Outlook, By Antacids (2023-2034) ($MN)
  • Table 21 Global Viral Gastroenteritis Market Outlook, By Laxatives (2023-2034) ($MN)
  • Table 22 Global Viral Gastroenteritis Market Outlook, By Chemotherapy Drugs (2023-2034) ($MN)
  • Table 23 Global Viral Gastroenteritis Market Outlook, By Other Drugs (2023-2034) ($MN)
  • Table 24 Global Viral Gastroenteritis Market Outlook, By Dosage (2023-2034) ($MN)
  • Table 25 Global Viral Gastroenteritis Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 26 Global Viral Gastroenteritis Market Outlook, By Injection (2023-2034) ($MN)
  • Table 27 Global Viral Gastroenteritis Market Outlook, By Other Dosages (2023-2034) ($MN)
  • Table 28 Global Viral Gastroenteritis Market Outlook, By Indication (2023-2034) ($MN)
  • Table 29 Global Viral Gastroenteritis Market Outlook, By Watery Diarrhea (2023-2034) ($MN)
  • Table 30 Global Viral Gastroenteritis Market Outlook, By Vomiting (2023-2034) ($MN)
  • Table 31 Global Viral Gastroenteritis Market Outlook, By Abdominal Pain and Cramps (2023-2034) ($MN)
  • Table 32 Global Viral Gastroenteritis Market Outlook, By Dizziness (2023-2034) ($MN)
  • Table 33 Global Viral Gastroenteritis Market Outlook, By Diarrhea (2023-2034) ($MN)
  • Table 34 Global Viral Gastroenteritis Market Outlook, By Nausea (2023-2034) ($MN)
  • Table 35 Global Viral Gastroenteritis Market Outlook, By Vomiting (2023-2034) ($MN)
  • Table 36 Global Viral Gastroenteritis Market Outlook, By Headache (2023-2034) ($MN)
  • Table 37 Global Viral Gastroenteritis Market Outlook, By Chills (2023-2034) ($MN)
  • Table 38 Global Viral Gastroenteritis Market Outlook, By Loss of Appetite (2023-2034) ($MN)
  • Table 39 Global Viral Gastroenteritis Market Outlook, By Fever (2023-2034) ($MN)
  • Table 40 Global Viral Gastroenteritis Market Outlook, By Joint Stiffness (2023-2034) ($MN)
  • Table 41 Global Viral Gastroenteritis Market Outlook, By Sweating (2023-2034) ($MN)
  • Table 42 Global Viral Gastroenteritis Market Outlook, By Muscle Pain (2023-2034) ($MN)
  • Table 43 Global Viral Gastroenteritis Market Outlook, By Weight Loss (2023-2034) ($MN)
  • Table 44 Global Viral Gastroenteritis Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 45 Global Viral Gastroenteritis Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 46 Global Viral Gastroenteritis Market Outlook, By Oral (2023-2034) ($MN)
  • Table 47 Global Viral Gastroenteritis Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 48 Global Viral Gastroenteritis Market Outlook, By Others (2023-2034) ($MN)
  • Table 49 Global Viral Gastroenteritis Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 50 Global Viral Gastroenteritis Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 51 Global Viral Gastroenteritis Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 52 Global Viral Gastroenteritis Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 53 Global Viral Gastroenteritis Market Outlook, By End User (2023-2034) ($MN)
  • Table 54 Global Viral Gastroenteritis Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 55 Global Viral Gastroenteritis Market Outlook, By Ambulatory Care Centers (2023-2034) ($MN)
  • Table 56 Global Viral Gastroenteritis Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.